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Abstract
Over-expression of inflammation associated enzyme cyclo-oxygenase (COX)-2 promotes
breast cancer progression, metastasis and sustains cancer stem-like cells (SLCs) by activating
prostaglandin E2 receptor EP4. Two COX-2 induced oncogenic miRNAs, miR-655 and miR526b, target and down-regulate the cytoplasmic polyadenylation element binding protein
(CPEB)-2. Hypothesis: Down-regulation of CPEB2 promotes an aggressive breast cancer
phenotype through SLC induction and epithelial to mesenchymal transition (EMT). We
found that high COX-2/miRNA expressing cell lines MDAMB231 and MCF7-COX-2 had
significantly lower expression of CPEB2 than MCF7 cells (low COX-2/miRNA). CPEB2
knockdown (KD) in CPEB2-high MCF7 cell line resulted in increased migratory and
invasive capacity in vitro. CPEB2 KD increased spheroid forming ability (SLC surrogate),
expression of SLC markers (Nanog, ALDH1, SOX-2), and mesenchymal marker (Twist1),
and decreased epithelial marker (E-Cadherin). Furthermore, treatment with COX-2 inhibitor
and EP4 antagonist increased CPEB2 expression. Collectively, CPEB2 demonstrates antioncogenic functions and CPEB2 inhibition promotes an aggressive breast cancer phenotype.

Keywords
Cyclo-oxygenase (COX)-2, cytoplasmic polyadenylation element binding protein (CPEB)-2,
breast cancer, stem like cells (SLCs), epithelial to mesenchymal transition (EMT),
Prostaglandin E receptor 4 (EP4)
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INTRODUCTION
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1.1 Overview of Cancer
Cancer is a disease that starts in the cells of various tissues in the body. Cancer cells
acquire mutations that progressively transform them into a malignant state. Reaching this
state is a multi-step process. Mutations leading to activation of growth promoting genes
(oncogenes) or deactivation of growth suppressor (tumour suppressor) genes typically
lead to cancer. Cancer cells develop mechanisms to avoid senescence, cell death signals
and expression of tumour suppressors (Hanahan & Weinberg, 2011).. They often break
out of normal tissue confines by increased migration and invasiveness. Cancer cells can
induce the formation of blood vessels (angiogenesis, to derive their own nourishment)
and sometimes new lymphatic vessels (lymphangiogenesis, which promotes lymphatic
metastasis). These processes allow them to metastasize to other parts of the body
(Hanahan & Weinberg, 2011). According to current statistics, one in nine Canadian
women are expected to develop breast cancer over their lifetime and one in twenty-nine
Canadian women will die from the disease (Canadian Cancer Society 2013). Breast
cancer accounts for the second highest cancer-related mortality in females (Canadian
Cancer Statistics).
Normal breast architecture consists of multiple milk-making glands that form a cluster of
lobules, which are connected to the nipple through interlobular ducts. The lobules and
ducts are surrounded by a layer of luminal and myoepithelial cells, and are separated
from surrounding tissue by a basement membrane. Breast cancer can be broken down
into categories based on histology. The two common types of non-metastatic breast
cancer are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), which
refer to cancers located in the milk ducts or milk-making glands. The tumour becomes
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invasive when the cells break down the basement membrane and from there spread to
surrounding breast tissue, and ultimately metastasize to other parts of the body.
Breast cancer can also be classified based on the presence or absence of specific
immunopathological markers. Treatment options and prognosis are often based on these
markers. The markers are comprised of the estrogen receptor (ER), progesterone receptor
(PR) and human epidermal receptor 2 (HER2) (Bertos & Park, 2011). The usual course of
treatment for ER+ tumours is anti-estrogen endocrine therapy, while HER2+ tumours are
linked with poorer prognosis and are usually treated with the HER2 inhibitor
Trastuzumab (Herceptin) (Vuong, Simpson, Green, Cummings, & Lakhani, 2014).
Breast cancer can be further classified according to mRNA transcription categories:
luminal A, luminal B, basal, HER2 and claudin low. Luminal A subtypes have higher
levels of Estrogen receptor 1 (ESR1) and ER regulated genes, lower ki-67 expression, a
marker for cell proliferation, and better survival rates compared to the luminal B subtype.
Claudin-low tumours are linked to poor outcomes, while the basal subtype is associated
with ER-/PR-/HER2- or the triple negative cohort, the most severe form of breast cancer
(Bertos & Park, 2011; Vuong et al., 2014). Despite these classifications, breast cancer
tumours contain a heterogeneous population of cells, which makes them harder to treat.
This heterogeneity might arise from a combination of mutations within cells and
differentiation of mutated stem like cells (SLCs) during cancer (Reya, Morrison, Clarke,
& Weissman, 2001). Traditional therapies are often unable to completely eradicate all
cancer cells, leaving behind the SLC tumour cell subset, which leads to tumour
reoccurrence. As such, there is a pressing need to identify novel drug targets and
biomarkers for therapeutic monitoring.
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1.2 Stem Like Cells
SLCs are a rare population of cells within the tumour that possess certain stem cell like
properties that drive the initiation and growth of tumours, and promote reoccurrence of
cancer (Campbell & Polyak, 2014; Reya et al., 2001). Normal stem cells persist in the
body through self-renewal properties, and are able to generate mature cells through
differentiation (Reya et al., 2001). The cancer stem cell model suggests that SLCs could
be derived from transformed stem cells, progenitor cells or differentiated cells (Reya et
al., 2001). The genetic makeup of SLCs is continuously evolving, giving them treatmentresistant properties that are passed down to daughter generations (Valent et al., 2012).
Quiescent SLCs can evade traditional therapies such as radiation and chemotherapy,
which target rapidly dividing cells that make up the bulk of the tumour population. This
causes a reduction in tumour size but is not a complete cure due to SLCs that exist in a
quiescent or dormant state (Kai, Arima, Kamiya, & Saya, 2010; Tysnes, 2010; Wicha,
Liu, & Dontu, 2006). Recent evidence suggests that SLCs adopt a functional state
dependent on extrinsic micro-environmental factors in the ―SLC-niche‖ (Visvader &
Lindeman, 2012). For instance, in colorectal cancer, myofibroblasts secrete factors which
are able to confer the stem cell phenotype in more differentiated tumour cells (Vermeulen
et al., 2010).
With advancements in technology, we are now able to address SLC properties in vitro.
One such assay cultures undifferentiated cells in spherical colonies referred to as
tumourspheres. These are grown under low-attachment (anchorage independent)
conditions in serum free medium supplemented with growth factors (Dontu et al., 2003).
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SLCs are also characterized by the presence or absence of cell surface markers and
enzyme activities. Tumourspheres in breast cancer were found to be enriched primarily
for undifferentiated cells and cells expressing surface markers CD44+/CD24- (Dontu et
al., 2003; Ponti et al., 2005). Cancer cells sorted for CD44+/CD24- phenotype displayed
increased tumourigenicity after injection into immune-compromised mice (Al-Hajj,
Wicha, Benito-Hernandez, Morrison, & Clarke, 2003). Aldehyde dehydrogenase
(ALDH) activity has also been associated with SLCs. ALDH is a cytoplasmic
detoxification enzyme and is highly expressed in multiple progenitor cell lineages
(Vasiliou & Nebert, 2005). CD44+/CD24-/ALDHhigh and CD44+/CD133+/ALDHhigh
cells demonstrated increased tumoursphere forming ability and lung metastasis following
tail vein injection in immune-compromised mice (Croker et al., 2009). Interestingly,
another study also found that high ALDH1 expression in DCIC breast biopsies is
associated with increased risk of breast cancer development (Kunju et al., 2011). In
addition, expression of pluripotency genes such as SOX-2, Nanog, OCT4 has also been
associated with SLCs in various cancers including the breast (Chiou et al., 2010; Ezeh,
Turek, Reijo, & Clark, 2005; Leis et al., 2012). Thus, SLCs may be prospectively
identified in breast cancer by the CD44+/CD24-/CD133+/ALDHhigh phenotype (Al-Hajj
et al., 2003; Croker et al., 2009). Targeting these SLCs in breast cancer may reduce
reoccurrence of cancer and improve patient survival.

1.3 Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is an important component of cancer
metastasis. Cancer metastasis is a complex process which involves the generation of
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motile tumour cells, breakdown and migration through the basement membrane and
migration into blood or lymphatic vessels, extravasation to a secondary site and
establishment of secondary tumours (Tsuji, Ibaragi, & Hu, 2009). At the sub-cellular
level, loss of tight junctions, adherens junctions and desmosomes, is observed as well as
cytoskeletal changes and differential expression of adhesion molecules and transcription
factors. During EMT, decreased expression of CDH1 (E-Cadherin) is associated with loss
of cell-cell contacts and epithelial cell polarity (Adams & Nelson, 1998; VincentSalomon & Thiery, 2003). There is also a concurrent increase in expression of
mesenchymal markers Twist1, Snail1 (Snail) and Zeb1 which are translational repressors
of E-Cadherin (Peinado, Olmeda, & Cano, 2007). Changes in cells from highly organized
epithelial like cells to a more motile mesenchymal cell are characteristics of cancer cell
plasticity (Thiery, 2002). Identifying cells prone to EMT will help us target cells that are
more likely to metastasize.

1.4 Cyclo-oxygenase Enzymes and Prostanoids
Over the past decade, our laboratory has pioneered the investigation into the role of
cyclo-oxygenase (COX) system in cancer promotion (Dunn, Majumder, & Lala, 2014;
Landman, Majumder, Liu, & Lala, 2014; Majumder, Xin, Liu, Girish, & Lala, 2014;
Rozic, Chakraborty, & Lala, 2001; Timoshenko, Lala, & Chakraborty, 2004; Xin et al.,
2012).

Elevated COX-2 expression was observed in approximately 85% of human

colorectal cancers and in 37.4% of breast cancer tumours compared to normal tissue
(Eberhart et al., 1994; Ristimaki et al., 2002). Furthermore, high expression of COX-2
has been demonstrated in hepatocellular carcinoma and lung cancer (Soslow et al., 2000;
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Tang, 2005). Aberrant cyclo-oxygenase (COX)-2 up-regulation during chronic
inflammation is believed to play a major role in carcinogenesis (FitzGerald, 2003).
COX enzymes catalyze the rate limiting step in the formation of prostanoids. There are
three isoforms of the enzyme, COX-1 and COX-2, and the lesser studied COX-3, which
is a variant of COX-1 (Chandrasekharan et al., 2002). COX-1 is constitutively expressed
in most tissues including the lungs, small and large intestine, liver, and kidney. It
generates steady and low levels of prostanoids needed for physiological functions such as
vaso-relaxation, platelet aggregation and protection of gastro-intestinal lining epithelia. In
contrast, COX-2 expression is induced locally in multiple tissues by inflammatory
cytokines and mitogens, producing high prostanoid levels required to combat pathogens
through mobilization of leukocytes into interstitial space (FitzGerald, 2003).
Production of prostanoids, in particular prostaglandin (PG)E2, depends mainly on COX-1
and COX-2 expression. When stimulated, arachidonate is cleaved from the lipid bilayer
by phospholipase-A2 (PLA2). Liberated arachidonic acid is then converted to
prostaglandin (PG)H2 in a two step reaction via the COX enzymes. Through different
cell-specific synthases, PGH2 is converted to signaling molecules, which include
Prostacyclin (PGI2), Thromboxane A2, Prostaglandin D2, Prostaglandin F2α and
Prostaglandin E2. These prostanoids subsequently mediate pleiotropic effects through
multiple receptors. Notably, PGE2 was determined to be the most abundant prostaglandin
released from breast cancer cells (Timoshenko, Xu, Chakrabarti, Lala, & Chakraborty,
2003). PGE2 mediates its effects through four different G-protein-coupled receptors, EP14.

8

EP1 activation is coupled with Gq and leads to increased intracellular calcium
mobilization. In contrast, PGE2 signaling is mediated primarily by EP2 and EP4 receptors
coupled with Gs, resulting in increased cyclic 3,5-adenosine monophosphate (cAMP),
whereas EP3 stimulation is coupled with G protein Gi and inhibits adenylate cyclase
activity resulting in decreased (cAMP) levels (Bos, Richel, Ritsema, Peppelenbosch, &
Versteeg, 2004). More recently, EP4 was also demonstrated to mediate its effects through
the phosphatidylinositol 3-kinase (PI3K) pathway which phosphorylates extracellular
signal-regulated kinases (ERKs) (Fujino & Regan, 2006; Fujino, Xu, & Regan, 2003).
This pathway is unique to EP4 and not utilized by EP2. Prostanoids mediate a complex
array of signaling pathways essential to homeostatic function, on the other hand
uncontrolled signaling has been implicated in cancer.

9

Figure 1. Cyclo-oxygenase enzymes, prostanoids and EP receptors
COX-1 and COX-2 convert arachidonic acid into prostaglandin precursors PGG2 and
PGH2 through a two step rate limiting reaction. PGH2 is converted to various prostanoids
through different prostanoid synthases. Most notably, COX enzymes mediate the
formation of PGE2, which has been associated with breast cancer aggressiveness. PGE2
acts on four different EP receptors. Our lab is investigating COX-2 mediated breast
cancer progression, focusing on the pathway highlighted in red.
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1.5 COX Inhibitors
Non-selective COX-1/COX-2 inhibitors are non-steroidal anti-inflammatory drugs
(NSAIDs) with Aspirin-like properties, and primarily utilized for analgesic, antiinflammatory and fever reducing activities (Flower, 2003). In the 1970s, Aspirin and
Aspirin-like-drugs were shown to reduce prostaglandin levels in humans (Smith & Willis,
1971). Interestingly, these drugs also showed promise as anti-cancer agents. For instance,
patients treated with low-dose Aspirin had a decrease in fatal colon cancer (Thun,
Namboodiri, & Heath, 1991). However, chronic use of NSAIDs is associated with
adverse effects such as gastric intolerance and delay of blood clotting. Selective COX-2
inhibitors, such as Celecoxib (Celebrex, Pfizer), have shown promising therapeutic
effects and chemoprotective effects in a variety of cancers (Harris, 2009). The use of
COX-2 inhibitors has exhibited increased apoptosis in head and neck carcinoma, reduced
tumour formation in colon cancer and breast cancer (Harris, Alshafie, Abou-Issa, &
Seibert, 2000; Kim et al., 2010; Sheng et al., 1997). However, prolonged use of COX-1
and COX-2 inhibitors has been associated with adverse cardiovascular events such as
myocardial infarction, cardiac arrest, stroke and pulmonary embolisms in a small subset
of patients (Fitzgerald, 2004; Graham, 2006; Nussmeier et al., 2005). The increased
incidence of cardiovascular events is believed to result from the inhibition of cardioprotective prostanoids such as PGI2; which blocks platelet aggregation and promotes
vaso-dilation (Fitzgerald, 2004). COX-2 inhibitors disrupt the balance of PGI2 and
thromboxane A2 present in the body (Fitzgerald, 2004). Thromboxane A2 plays a role in
vasoconstriction and platelet aggregation, and is mainly produced by COX-1 thus
generally unaffected by selective COX-2 inhibitors. Because PGE2 signals through EP4
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via a unique pathway not shared by other EPs, our lab is investigating the receptor as
more selective down-stream target of COX-2 activity that avoids cardiovascular sideeffects observed with prolonged use of COX-2 inhibitors.

1.6 COX-2 and Breast Cancer
COX-2 has an important role in breast cancer progression. In tumours, COX-2 expression
has been correlated with negative hormone receptor (ER and PR) status and HER2
amplification (Ristimaki et al., 2002) (Majumder et al. submitted Oncogene).
Furthermore, studies in our laboratory have demonstrated that ectopically expressed
COX-2 in breast cancer cell lines increase cell migration, invasion and proliferation
(Majumder et al. submitted Oncogene). Increased proliferation is also a characteristic of
COX-2 high tumours (Ristimaki et al., 2002). In breast cancer tissue, high COX-2 has
been associated with matrix metalloproteinase (MMP)-2 activation, which degrade
components in the extracellular matrix and the basement membrane (Sivula et al., 2005).
Furthermore, high COX-2 expression is associated with high VEGF-C and LYVE-1,
markers for endothelial lymphatic cells (Timoshenko, Chakraborty, Wagner, & Lala,
2006), and COX-2 over-expression demonstrated up-regulated production of angiogenic
(VEGF-A) and lymphangiogenic (VEGF-C and –D) factors (Timoshenko et al., 2006)
(Majumder et al. submitted Oncogene). Furthermore, COX-2 transfection markedly
increased the size and frequency of clonogenic spheroid formation (a surrogate of SLC
function in vitro) (Majumder et al. submitted Oncogene). Tumourspheres formed from
COX-2 over-expressing cells had increased co-expression of the breast cancer stem cell
markers CD44 and ALDH, as well as embryonic stem cell pluripotency markers SOX-2
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and OCT-3/4 (Majumder, Xin, Liu, Girish, et al., 2014) (Majumder et al. submitted
Oncogene). EMT phenotype was observed in COX-2 over-expressing breast cancer cells,
shown by decreased expression of epithelial marker CDH1 and increased expression of
mesenchymal markers VIM (Vimentin), Twist1 and CDH2 (N-Cadherin) (Majumder,
Landman, Liu, Hess, & Lala, 2015) (Majumder et al. submitted Oncogene). Finally,
COX-2 over-expressing cells demonstrated a marked increase in lung colony forming
ability and orthotopic tumourigenicity after serial transplantation into immunodeficient
murine recipients (Majumder et al. 2014). Collectively, these observations are consistent
with increased metastasis and reduced survival in breast cancer patients with high COX-2
expression within tumours (Ristimaki et al., 2002).

1.7 PGE2 and Breast Cancer
As mentioned previously, PGE2 is the main prostainoid resulting from increased COX-2
activity in breast cancer cells (Timoshenko et al., 2003). Our lab has shown that PGE2
promotes tumour progression and metastasis by multiple mechanisms; (1) including the
inactivation of cancer-fighting immune cells (Lala, Santer, Libenson, & Parhar, 1985;
Parhar & Lala, 1985), (2) stimulation of cancer cell migration (Rozic et al., 2001;
Timoshenko et al., 2003) and invasion (Timoshenko et al., 2004), (3) cancer-associated
angiogenesis (Rozic et al., 2001), and (4) lymphangiogenesis by up-regulation of VEGFC or VEGF-D (Timoshenko et al., 2006; Xin et al., 2012). Therefore, COX-2 mediated
production of PGE2 promotes cancer associated functions.
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1.8 COX-2 induced miRNAs in breast cancer
MicroRNAs (miRNAs) are small regulatory RNA molecules (19-24 nucleotides) that are
transcribed from DNA but not translated into protein. miRNAs act to down-regulate gene
expression at the post-transcriptional level by either degrading mRNA of their target gene
or by blocking translation of the target gene into protein. They recognize their target gene
through sequence complementarity, usually located on the target gene‘s 3‘untranslated
region (UTR) (Sassen, Miska, & Caldas, 2008). MiRNA biogenesis starts with RNA
polymerase II or III driven generation of pri-miRNA strands. Drosha RNase III
endonuclease performs nuclear cleavage of the the pri-miRNA strand, generating a stem
loop structure intermediate or the miRNA precursor (pre-miRNA). The pre-miRNA is
then transported to the cytoplasm by Ran-GTP and Exportin-5. Next, Dicer cleaves the
pre-miRNA, removing the loop and terminal base pairs. This produces the mature
miRNA and a similar sized complementary fragment referred to as the miRNA*. The
miRNA:miRNA* duplex is short lived and the miRNA* is subsequently degraded. The
mature miRNA is incorporated into the RNA-induced silencing complex (RISC), which
then suppresses target gene expression (Bartel, 2004). MiRNAs have been associated
with oncogenic and anti-oncogenic (tumour-suppressor-like) functions. Interestingly,
miRNAs can be found in body fluids within micro-vesicles (Kosaka, Iguchi, & Ochiya,
2010). Therefore, expression of certain miRNAs can be utilized as potential cancer
biomarkers (Calin & Croce, 2006).
Affymetrix microRNA micro-array comparison of the MCF7-COX-2 cells and MCF7Mock cells, identified two miRNAs, miR-526b and miR-655, that are up-regulated in the
COX-2 over-expressing cell lines. COX-2 low breast cancer cells treated with PGE2 or
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EP4 agonists had higher expression of miR-526b and miR-655 (Majumder et al., 2015)
Furthermore, COX-2 over-expressing tumourspheres demonstrated higher expression of
these miRNAs, suggesting that these miRNAs are COX-2 and EP4 induced (Dunn et al.,
2014; Majumder, Postovit, et al., 2014). MiR-526b and miR-655 over-expressing cells
also showed increased migration, invasion, proliferation and tumoursphere formation
(Dunn et al., 2014; Majumder et al., 2015). When these miRNA over-expressing cells
were treated with EP4 antagonists, a reduction in spheroid formation was observed. In
vivo studies of these miRNA over-expressing breast cancer cells revealed an increase in
proliferative lung colonies in mice compared to MCF7-Mock cells (Majumder et al.,
2015; Majumder, Xin, Liu, Bell, et al., 2014). In situ studies demonstrate that both miR526b and miR-655 are higher in breast cancer tissue and are negatively correlated with
patient survival (Majumder et al., 2015; Majumder, Postovit, et al., 2014). Therefore,
miR-526b and miR-655 are considered oncogenic with SLC-inducing properties which
are mediated through COX-2 and EP4. Interestingly, cytoplasmic polyadenylation
element binding protein (CPEB)-2 is the common gene target for both miRNAs. By
extension, we propose that CPEB2 may demonstrate anti-oncogenic properties, and
down-regulation of CPEB-2 by miR-526b and miR-655 promotes breast cancer
aggressiveness.

1.9 The CPEB Family of Proteins
Translation of eukaryotic mRNAs can be regulated through the length of their poly(A)
tails (Macdonald, 2001). CPEB1, the founding member of the CPEB family, was first
described to play a role in oocyte maturation (Hake & Richter, 1994). CPEB1 regulates
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translation by associating with specific sequences in the 3‘ UTR of their target mRNA
called

cytoplasmic

polyadenylation

elements

(CPEs,

sequence:

UUUUUAU)

(D‘Ambrogio, Nagaoka, & Richter, 2013; Hake, Mendez, & Richter, 1998). All CPEBs
have some common structural elements including an N-terminal regulatory domain and a
C-terminal RNA-binding domain. The RNA-binding domain contains two RNA
recognition motifs (RRMs) and a cysteine-histidine zinc finger region, which when
deleted impair the ability of CPEBs to bind to target mRNAs (Hake et al., 1998). Based
on amino acid homologies in the coding regions and RNA binding regions (RRMs and
zing finger regions), human CPEBs can be divided into two subfamilies: CPEB1 and
CPEB2-4 (Huang, Kan, Lin, & Richter, 2006; Kurihara et al., 2003). The RNA binding
domains of CPEB2, CPEB3 and CPEB4 are very similar, suggesting that they might
share similar recognition sequences (Kurihara et al., 2003).
Unlike CPEB1, CPEB3 and CPEB4 do not interact with CPEs and bind other RNA
binding sequences (Huang et al., 2006). Furthermore, unlike CPEB1, CPEB3 does not
bind the cleavage and polyadenylation specificity factor (CPSF) (Huang et al., 2006).
This suggests that CPEB3 and CPEB4 do not regulate translation through
polyadenylation and do so through an independent mechanism. Although little is known
on CPEB2 function, it is postulated that since CPEB2 is more similar to CPEB3-4 than
CPEB1, then CPEB2 RNA binding sequences should be similar to CPEB3-4 and not
CPEB1. However, a more recent paper highlights that both CPEB1 and CPEB2 bind to
the CPE in HIF-1α RNA, to regulate its protein expression (Hägele, Kühn, Böning, &
Katschinski, 2009). This suggests that CPEB2 regulates translation through
polyadenylation and possibly another mechanism similar to CPEB3-4.
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CPEB1 has been associated with cellular senescence, loss of polarity and suppression of
malignancy (D‘Ambrogio et al., 2013). CPEB1 knock-out mouse embryonic fibroblast
cells avoid senescence and continue to divide (Groisman et al., 2006). When CPEB1 is
re-introduced into CPEB1 low cells, cell stop dividing and express senescence associated
marker β-galactosidase (Burns & Richter, 2008; Groisman et al., 2006). CPEB1 has also
been shown to play a role in synaptic plasticity by regulating the translation
α‐Ca2+/calmodulin‐dependent protein kinase II (αCaMKII) mRNA (Huang, Jung,
Sarkissian, & Richter, 2002; Wu et al., 1998). Meta-analysis of global gene expression in
cancers compared to normal tissues has shown that CPEB1 mRNA is lower in brain and
reproductive system cancer, and CPEB3 mRNA is lower in digestive tract cancer, brain
tumours and, head and neck tumour (D‘Ambrogio et al., 2013). On the other hand,
CPEB4 mRNA is higher in pancreatic glioblastomas (D‘Ambrogio et al., 2013).

1.9.1

CPEB2

In mouse organs, CPEB2 RNA has been detected in large quantities in the testis, and is
also found at lower levels in the brain, liver, thymus, salivary glands, spleen, kidney,
intestines and ovaries (Chen & Huang, 2012; Kurihara et al., 2003). The amount of
CPEB2 in breast tissue has not been investigated. HeLa cells transfected with a CPEB2GFP construct demonstrated that the protein is localized in the cytoplasm in cells (Huang
et al., 2002; Kurihara et al., 2003). The role of CPEB2 in breast cancer has not been
studied, but it may represent an important therapeutic target for cancer therapy due to its
known targets.
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1.9.2

CPEB2 Targets

Genes involved in antioxidant defence systems, such as hypoxia inducible factor (HIF)1α, are up-regulated in breast cancer stem cells (Kai et al., 2010). HIF-1α over-expression
in cancer has been associated with increased patient mortality in cancers of the brain,
breast, cervix, oropharynx, ovary, and uterus (Semenza, 2003). HIF-1α has been shown
to up-regulate genes involved in apoptosis resistance, angiogenesis and metastasis
(Semenza, 2003). Under normoxic conditions, CPEB2 interacts with eukaryotic
elongation factor (eEF)-2 and binds to the 3‘UTR of HIF-1α, reducing HIF-1α peptide
elongation (Chen & Huang, 2012). Under arsenite induced stress, CPEB2 is released
from HIF-1α RNA and no longer interacts with eEF2. This allows eEF2 to resume
maximum GTPase activity and increases the translation of HIF-1α (Chen & Huang, 2012;
Hägele et al., 2009), leading to up-regulation of hypoxia induced factors such as VEGF.
Nairismägi et al. (2012) have shown that CPEB2 also has a role in the posttranscriptional regulation of Twist1, a gene involved in the EMT transition. Using
immuno-precipitation, the authors determined that CPEB2 associates with Twist1 mRNA
and over-expressing CPEB2 leads to decreased Twist1 protein levels (Nairismägi et al.,
2012). Recently, β-catenin,

CaMKIIα, and ephrin receptor A4 (EphA4) have been

identified as CPEB2 targets in mouse brain (Turimella et al., 2015). β-catenin and
CaMKIIα are also established CPEB1 targets (Hägele et al., 2009; Wu et al., 1998). This
shows that there is an overlap of target molecules between CPEB1 and CPEB2.
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1.9.3

MiRNAs and CPEB2

CPEB2, along with CPEB3-4, have previously been shown to be negatively regulated by
miR-92 and miR-26. Both these miRNAs bind to the predicted recognition motif in the 3‘
UTR of CPEB2-4 and reduce transcript levels (Morgan, Iaconcig, & Muro, 2010). MiR92 is up-regulated in certain human cancers, is associated with increased proliferation and
reduced apoptosis, and is inversely correlated with estrogen receptor β1 (Erβ1) in breast
cancer cell lines (Al-Nakhle et al., 2010; Manni et al., 2009; Shigoka et al., 2010;
Tsuchida et al., 2011; Ventura et al., 2008). On the other hand, miR-26 has both
oncogenic and tumour suppressive roles, where it has high expression in high grade
glioma cells and reduced expression in breast cancer tumour tissues (Huse et al., 2009;
Zhang et al., 2011).
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1.10

Rationale

Our laboratory has previously shown that COX-2 promotes aggressive properties and
induces a SLC phenotype in breast cancer cells; and that these functions are at least in
part mediated by PGE2, EP4 and COX-2-induced miR-526b and miR-655. Stable
transfection of COX-2 into human breast cancer cell lines MCF7 (COX-2 low, ER+,
HER2–) and SKBR3 (COX-2 low, ER–, HER2+), induced all the phenotypic properties
of aggressive breast cancer in vitro and in vivo (Majumder, Postovit, et al., 2014).
Therefore, a combined Affymetrix gene expression and microRNA analysis of the COX2 transfected cells compared to the mock transfected cells was performed. Out of the 848
microRNAs tested, only two were up-regulated by COX-2 transfection, miR-526b and
miR-655. At the same time, out of 28,870 genes tested only 26 were down-regulated with
COX-2 transfection. Interestingly, out of the 26 down-regulated genes, either miR-655 or
miR-526b targeted 13 genes identified through the micro-array. The only common gene
target of both miR-655 and miR-526b was CPEB2. Since both oncogenic miR-655 and
miR-526b have target sites of the 3‘ untranslated region (UTR) of CPEB2, and miRNAs
down-regulate specific gene expression, we postulate that CPEB2 might have an antioncogenic role in breast cancer.
Since microRNAs are stable in patient‘s serum, these oncogenic miRNAs can serve as
potential markers for screening of SLCs and therapeutic responses in the clinic.
Furthermore, gene expression profiles can be important prognostic markers in cancer.
Thus, establishing a tumour-suppressor-like role for the CPEB2 will allow us to identify
CPEB2 as a novel therapeutic target for tumour suppression in breast cancer.
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1.11

Central Hypothesis:

Down-regulation of CPEB2 promotes an aggressive breast cancer phenotype through
SLC induction and EMT.

Specific Aims
1) To investigate if there is an inverse relationship between expression levels of a)
CPEB2 and COX-2 and b) CPEB2 and miR-655 or miR-526b in human breast
cancer cell lines.
2) To elucidate the effects of CPEB2 knock-down on MCF7 cell migration,
invasion, proliferation, SLC function, and EMT in vitro
3) To investigate the effects of COX-2 inhibitor, and PGE2 (EP1-4 ligand), EP4
agonist and antagonist treatments on CPEB2 levels.
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2

EXPERIMENTAL METHODS
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2.1 Cell Culture
The breast cancer cell lines used in this project are summarized in Table 1. All cells were
purchased from the American Type Culture Collection (ATCC). MCF7 cells were
extensively used in this thesis. MCF7 cells originated from the mammary gland of a
patient with adenocarcinoma (ATCC, 2015). These cells are ER and PR positive, and
HER2 negative (Kao et al., 2009). Furthermore, MCF7 cells are low in COX-2
(Majumder, Postovit, et al., 2014) and high in CPEB2, making them ideal candidates for
CPEB2 knockdown in this study.
All breast cancer cell lines were maintained as monolayers in T-75 cm2 flasks (Falcon) in
a humidified incubator with 5% CO2 at 37°C. MCF7 cells were grown in Eagle‘s
Minimum Essential Media (EMEM, ATCC) supplemented with 10% Fetal Bovine Serum
(FBS, Gibco), 100 µg/mL of penicillin/streptomycin (pen/strep, Gibco) and 10 µg/mL of
insulin (Sigma). SKBR3 cells were grown in McCoy‘s 5A Modified Media (Gibco), and
MDAMB231, HS578T and T47D cells were grown in RPMI-1640 Media (Gibco)
supplemented with 10% FBS and 100 µg/mL pen/strep. Cells were washed with DPBS
(Gibco) and media was changed every 48 hours. Cells were detached with 0.25% Trypsin
(Gibco) and re-plated, as required.

2.2 COX-2, CPEB2, miR-655 and miR-526b status in breast cancer cell lines
To determine the status of COX-2 and CPEB2 expression, miR-655 and miR-526b in
different breast cancer cell lines, real-time PCR was performed using the TaqMan gene
expression assay as described in ‗2.5‘.
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2.3 MCF7 Cell Transfection
Over-expression of COX-2 was achieved using a pCMV-IRES2-EGFP-COX-2 vector
which contained a cytomegalovirus (CMV) promoter. The plasmid also contains an
enhanced green fluorescence protein (EGFP) and neomycin resistance genes which can
be used to sort transfected cells.
Dr. Mousumi Majumder previously transfected MCF7 cells with 2 µg of either pCMVIRES-EGFP (control) plasmid or pCMV-IRES2-EGFP-COX-2 over-expression plasmid
(Dr. Michael Archer, University of Toronto). The resulting cell line was named MCF7COX-2. COX-2 over-expression was validated with real-time PCR as described in ‗2.5‘.
Media was supplemented with 500 µg/mL of Geneticin® (Gibco) to maintain selective
pressure.

2.4 Nucleofection
Electroporation is a transfection method that involves the application of short electronic
pulses to cells, which increase their permeability to macromolecules (Iversen, Birkenes,
Torsdalen, & Djurovic, 2005). To increase transfection efficiency, nucleofection was
employed. Nucleofection involves cell-specific delivery systems (nucleofector solution)
and electronic pulses to optimize delivery of DNA, small-interfering RNA (siRNA)
oligonucleotides to the nucleus of cells (Han et al., 2008). Nucleofection was performed
using the Amaxa Biosystems Nucleofector® 2 system, the Cell Line Nucleofector® Kit
V (Lonza) and associated protocol. The nucleofection protocol was validated by
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transfecting MCF7 cells with the supplied pmaxGFP Vector® (Lonza). Expression of
GFP was confirmed by fluorescence microscopy in MCF7 cells.

2.4.1

CPEB2 knockdown with siRNAs

In vitro CPEB2 knockdown was achieved using siRNAs. Similar to miRNAs, siRNAs
bind and degrade target genes with complementary mRNA sequences through RISC
(Carthew & Sontheimer, 2009). For this project, siRNAs were transfected into MCF7
cells to down-regulate CPEB2 expression. Parental MCF7 (COX-2 low) human breast
cancer cell line expressed high levels of CPEB2. MCF7 cells were grown until 80%
confluent in T-75 cm2 flasks (Falcon). Cells were trypsinized and pelleted. Two million
cells were transferred into certified cuvettes along with supplemented nucleofector®
solution (Lonza) and 1 µM of either CPEB2 siRNA (OriGene) or Universal Scrambled
Control siRNA ([Control siRNA], OriGene). The program used for transfection was P020. After nucleofection, cells were incubated at 37°C and 5% CO2 in appropriate
antibiotic free media. After 24 hours media was changed and experiments were
conducted after 48 hours. The resulting cell lines were named MCF7-Scrambled and
MCF7-CPEB2 KD. CPEB2 KD was validated using RT-PCR. To look at the functional
role of CPEB2, the following assays were tested: migration (Transwell assay), invasion
(Matrigel Transwell Assay), proliferation (BrdU uptake), EMT phenotype (real-time
PCR/IF) and in vitro SLC content (clonogenic tumoursphere formation on ultra-low
attachment plates/IF).
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2.5 Quantification of CPEB2 knockdown with polymerase chain reaction (RT-PCR)
Real-time polymerase chain reaction (real-time PCR) was used to quantify the amount of
specific mRNA transcripts present in a sample using fluorescent technology. We used a
multi-step protocol that involves: (1) RNA purification, (2) conversion of RNA into
cDNA, and (3) detection of PCR product (Fraga, Meulia, & Fenster, 2008). In general,
the less time it takes for an amplified target sequence to pass the detection threshold, the
greater the amount of target sequence there is in the starting material (Fraga et al., 2008).
Cells were grown until 80-90% confluent, after which they were trypsinized and pelleted.
Total RNA and miRNA was extracted using RNeasy Minikit and RNeasy MiniElute
Cleanup Kit (Qiagen) by following manufacture‘s protocol (Qiagen, 2010a, 2010b). Total
RNA and miRNA concentration was quantified using the Epoch Microplate
Spectrophotometer (BioTek®).
RNA and miRNA was converted into cDNA using a RNA-dependent DNA polymerase
(Reverse Transcriptase). cDNA was synthesized using reagents from the High Capacity
cDNA Reverse Transcription Kit

and

TaqMan MicroRNA Reverse Transcription Kit

(Life Technologies). In the case of RNA synthesis, random primers were used, while for
miRNA synthesis 3 µL of specific primers for miR-526b, miR-655, RNU44 and RNU48
(Life Technologies) were used. For each sample, 1 µg of RNA per 20 µL reaction or 0.5
µg of miRNA per 28 µL reaction were used to synthesize cDNA using the C1000™
Thermal Cycler (BioRad). The following parameters were used to perform reverse
transcription from RNA: hold for 10 min at 25°C, 120 min at 37°C, 5 min at 85°C, then
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hold at 4°C; and from miRNA: hold for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C,
then hold at 4°C.
For accurate detection of PCR product, PCR mixture was made using reagents from the
TaqMan Universal PCR Master Mix (RNA) and TaqMan Universal PCR Master Mix, no
AmpErase UNG kit (miRNA, Life Technologies). Each qPCR reaction tube was prepared
to a volume of 20 µL with 1 µL of appropriate TaqMan Probe, and 2 µL of cDNA. The
probes that were used in this experiment are listed in Table 2. House-keeping genes βactin and RPL5 (for RNA), and RNU44 and RNU48 (for miRNA) were used as controls.
The real-time PCR was performed on the Rotor-Gene 3000 (Corbett Research), using the
profile: hold for 2 min at 50°C, 10 min at 95°C followed by 45x cycling with denaturing
15 sec at 95°C, and anneal/extension cycles for 1 min at 58°C.
Data was analysed using the relative quantification method (2-ΔΔCT), where change in
expression of a target gene from a treated or transfected group was compared to a control
group (Livak & Schmittgen, 2001).

2.6 Transwell Assay
2.6.1

Migration Assay

MCF7-Parental cells, MCF7-Scrambled, and MCF7-CPEB2 KD were grown until 80%
confluent. Cells were serum starved in basal EMEM media overnight. A 24-well cell
culture plate fitted with 8 µm microporous polycarbonate cell culture inserts (Fisher
Scientific) was used to measure migration. The upper chamber contained 300 µL of cell
suspension (2 x 105 serum starved cells/mL of basal EMEM), while the bottom contained
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700 µL of EMEM media with no FBS or 5% FBS. Both sides of the insert membranes
were cell culture pre-treated to promote membrane cell-adherence and limit cell-growth
on the walls of the insert. Cells that adhered to the bottom surface of the membrane
inserts were counted as migratory cells.
Previous work in the laboratory has shown that peak migration occurs at 24 hours (Rozic
et al., 2001). Therefore, plates were incubated at 37°C and 5% CO2 for 24 hours after
which membrane inserts were removed and the top of the membrane inserts were wiped
carefully with a cotton swab to remove non-migratory cells. The membranes were fixed
with cold 100% methanol and stained with Eosin and Thiasine (VWR), which stains the
cytoplasm pink and nucleus purple. The membrane was then carefully removed from the
inserts and mounted onto microscope slides. Cells from the whole insert were counted
under a light microscope (Leica-DFC295).

2.6.2

Invasion Assay (Matrigel)

Another characteristic of the tumour cell metastatic phenotype is proteolytic activity that
degrades the extracellular matrix (ECM) barrier (L. M. Shaw, 2005). Once cells have
breached this barrier they can access the vasculature and lymphatic system (L. M. Shaw,
2005). The protocol for this experiment is similar to ―2.6.1 Transwell Migration Assay‖,
except that the upper section of the micro-porous polycarbonate membranes were coated
with a Matrigel gelatinous protein mixture, which mimics the basement membrane.
Matrigel is isolated from Englebreth-Holm-Swarm mouse sarcoma, and contains a
mixture of basement membrane ECM proteins such as laminins, collagen IV, and
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enactins (Hughes, Postovit, & Lajoie, 2010). The mixture was prepared by mixing
Growth Factor Reduced Matrigel® (VWR) in 1:100 dilution with cold EMEM. Then,
100 µL of diluted Matrigel was transferred onto the microporous polycarbonate
membranes and left overnight to polymerize at room temperature. Before plating the
cells, the matrigel layer was re-constituted with warm media for 30 mins at 37°C. Three
hundred microliters of cell suspension (2 x 105 serum starved cells/mL of basal EMEM)
was transferred to the upper well. As previously described, 700 µL of media (no FBS or
5% FBS) was transferred to the bottom well. Cells were incubated for 48 hours, which
was time period that showed the highest invasion as determined by previous work in the
laboratory (Rozic et al., 2001). Membranes were fixed, stained and invading cells were
counted.

2.7 Bromodeoxyuridine (BrdU) Assay and Enzyme-Linked Immunosorbent Assay
(ELISA)
Cellular proliferation requires the synthesis of new DNA. The Bromo-deoxyuridine
(BrdU) assay measures the incorporation of BrdU into newly synthesizing DNA. BrdU is
a pyrimidine analogue and is able to base pair with adenine during DNA replication. The
incorporation of BrdU is used as a measure of cell proliferation (Porstmann, Ternynck, &
Avrameas, 1985).
BrdU incorporation was detected using the Cell Proliferation ELISA, BrdU (colorimetric)
Kit (Roche) following manufacture‘s protocol (Roche, 2010). Cells (100 µL at 104
cells/mL) were transferred into a 96-well tissue culture microplate and incubated at 5%
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CO2 and 37°C for 24 hours. Ten microliters of 100 µM BrdU was added to the cells and
the cells were re-incubated at 37°C for 6 h. The labeling medium was removed and 200
µL of FixDenat solution was added to fix cells for 30 min at room temperature. The
solution was removed and 100 µL of anti-BrdU POD working solution was added to each
well for 90 min. The anti-BrdU-POD binds to the BrdU in the denatured newly
synthesized DNA. Following incubation, wells were washed three times with 200 µL of
washing solution (1x PBS), after which 100 uL of substrate solution was added per well
for 30 min. BrdU incorporation was quantified using an Epoch Microplate
Spectrophotometer at a wavelength of 370 nm with a reference wavelength of 492 nm.

2.8 Tumoursphere Formation Assays
Non-adherent tumourspheres can be clonally derived from cells with stem cell properties
(Dontu et al., 2003). MCF7 cells were grown until 80% confluent, trypsinized and resuspended in HuMEC media (Life Technologies) supplemented with epidermal growth
factor (EGF, 20 ng/mL), fibroblast growth factor basic (FGFb, 20 ng/mL) and B-27®
Supplement (1X, Invitrogen). To ensure that cells are plated as single cells, the solution
was passed through a 27 ½ G needle (BD) and a 40 µM strainer (Falcon). Five cells per
well were plated into 96-well ultra-low attachment plates (Corning) for 7 days or until
tumourspheres reached a size of at least 60 µm in diameter (F. L. Shaw et al., 2012).
Spheroids were counted and photomicrographs were taken using a light microscope
(Leica-DFC295). Spheroid formation efficiency
calculated.

was also
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2.9 Cell Staining for Immuno-fluorescence Microscopy
2.9.1

Adherent cells

MCF7-Parental, MCF7-Scrambled, and MCF7-CPEB2 KD cells were grown until 80%,
harvested with trypsin, and 4 x 104 cells were plated on cover-slips. After 24 hours cells
were rinsed with PBS. To fix the cells, covers-slips were immersed in 4% paraformaldehyde solution (Electron Microscopy Sciences) at room temperature for 30 min,
and rinsed with PBS three times. For cell permeabilization, 0.5% Triton-X100 (J T Baker
Chemical Co.) in PBS was added for 10 min at room temperature, followed by three
times PBS wash. Cells were blocked in 4% BSA in PBS with 0.01% Tween® 20 (Sigma)
for 30 min. After rinsing with PBS, cells were incubated with primary antibody (Table 3)
in 4% BSA in PBS at 4°C overnight. If the primary antibody was conjugated to a
fluorochrome, incubation with secondary antibody was not necessary. If not, the slides
were rinsed with PBS and incubated with secondary antibody in 4% BSA in PBS for an
hour. Twenty microliters of VECTASHIELD® Mounting Medium with DAPI (Vector
Laboratories) was added on to the cover-slip and transferred onto a slide. The following
primary antibodies were tested: E-Cadherin, Twist1, Nanog and ALDH1.
Fluorescence intensities for Twist1 and E-Cadherin were calculated using ImageJ
software. The raw integrated density was calculated for each cell and normalized to the
cell area. Data were presented as an average of all the cells.
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2.9.2

Non-adherent cells (Tumourspheres)

Cells were grown until 80% confluent, trypsinized and re-suspended in supplemented
HuMEC media following protocol outlined in tumoursphere formation assay. Ten
thousand cells per mL cells were plated in 6-well non adherent cell culture plates for 5
days or until the tumourspheres reach a size of 60 µm in diameter. After which, the
tumourspheres and media were transferred into a 1.5 mL Eppendorf tube and left on the
bench for 15 min to allow the tumourspheres to settle to the bottom. Media was carefully
removed by manual pipetting and the tip of the pipette was cut to maintain spheroid
structure. The fixation, permeabilization, and anti-body staining for non-adherent cells
were identical to the protocol described previously for adherent cells. The only exception
is that tumourspheres were allowed to settle for 1-2 min between PBS rinses to minimize
loss. The following primary antibodies were tested: ALDH1, SOX-2, and Nanog.
Quantification of fluorescence for ALDH1, Nanog, and SOX-2 were presented as ratio of
cells with positive staining to the total number of cells marked by DAPI.

2.10

COX-2 inhibitors, PGE2, EP4 Antagonists and Agonist Experiments

MCF7-COX-2 (5x104) cells were plated onto 6-well plates. Cells were serum starved
overnight, after which they were washed with PBS and incubated for 24 hours with
Celecoxib (10 or 20 µM), ONO-AE3-208 (10 or 20 µm) or vehicle control (0.003%
DMSO). Celecoxib is a selective COX-2 inhibitor while ONO-AE3-208 is a selective
EP4 antagonist.
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To address the effect of PGE2 activity and EP4 signaling, MCF7 (5x104) cells were
plated onto 6-well plates. Cells were serum starved overnight, washed with PBS and
incubated for 24 hours with PGE2 (10 µM) or PGE1OH (10 µm) or vehicle control
(EtOH). PGE2 is a natural ligand for all EP receptors, while PGE1OH acts as a selective
agonist for EP4.
For all treated cells, RNA and miRNA was extracted as previously described, converted
to cDNA and real-time PCR was performed to quantify the expression of CPEB2.

2.11

Statistical Analysis:

Statistical analyses were performed using GraphPad Prism Software Version 5.01
(GraphPad Software Inc 2007). Data compared non-transfected, Scrambled and CPEB2KD cell lines using one-way ANOVA followed by Tukey‘s post hoc test or Scrambled
and CPEB2-KD cells using unpaired students t-test. Results were considered statistically
significant if p<0.05.
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3

RESULTS
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3.1 Inverse relationship of CPEB2 with COX-2, miR-655 and miR-526b expression
Differential gene and miRNA microarray analysis of MCF7 breast cancer cells stably
transfected with COX-2 over-expressing plasmid revealed down-regulation of 26 genes
and up-regulation of two miRNAs. These two miRNAs, miR-655 and miR-526b, have
been found to be oncogenic by our lab (Dunn et al., 2014; Majumder et al., 2015).
Furthermore, their expression has been positively correlated with COX-2 expression. Out
of the 26 genes suppressed by COX-2 expression, thirteen are targeted by either miR-655
or miR-526b, with CPEB2 the only putative gene target of both miRNAs. Expression of
COX-2, miR-655, miR-526b and CPEB2 was quantified in different breast cancer cell
lines. Cell lines with high COX-2 and miRNAs expression, showed low expression of
CPEB2 (Figure 2), reinforcing the inverse relationship suggested by the differential gene
and miRNA microarray analyses previously performed (Majumder et al., 2015).
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Figure 2. Breast cancer cell lines with high COX-2, and miR-655 and miR-526b
expression demonstrate low CPEB2 expression
A. We hypothesized that cells with high COX-2 have increased expression of oncogenic
miR-655 and miR-526b, and low expression of CPEB2. B. RNA and miRNA was
extracted from 4 distinct breast cancer cell lines with disparate COX-2 expression. Data
are presented as average fold change normalized to MCF7-Parental (2-ΔΔCT) ± SEM. βActin and RNU-44 were used as internal controls for RNA and miRNA respectively.
High COX-2 expressing cell lines, MCF7-COX-2 and MDAMB231, showed high
expression of miR-526b and miR-655 and low expression of CPEB2. (*: p<0.05, **:
p<0.005, ***: p<0.0005) indicates a significant difference compared to MCF7 cells (oneway ANOVA, Tukey‘s post hoc test, n=3).
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A.

B.
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3.2 Validation of CPEB2 knockdown (KD) with small interfering RNA (siRNA)
MCF7 cells (ER+/PR+/HER2-) are low in COX-2, miR-655, miR-526b and high in
CPEB2 mRNA expression. To investigate the functional role of CPEB2 in vitro, CPEB2
expression was suppressed in MCF7 cells using siRNAs targeting CPEB2 and a universal
scrambled siRNA control at 1µM concentrations. The resulting cell lines were labeled as
MCF7-CPEB2 KD and MCF7-Scrambled. CPEB2 expression was quantified in nontransfected (MCF7-Parental), MCF7-Scrambled and MCF7-CPEB2 KD using real-time
PCR (2-ΔΔCT). MCF7-CPEB2 KD cells demonstrated significant down-regulation of
CPEB2 compared to Parental cells (Figure 3).
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Figure 3. MCF7 cells transfected with CPEB2 siRNA have significantly lower
expression of CPEB2
MCF7 cells were transfected with human CPEB2 siRNA (1 µM) and universal scrambled
negative control siRNA. Resulting cell line, MCF7-CPEB2 KD showed 70% downregulation of CPEB2 compared to non-transfected MCF7-Parental cell line using relative
quantification of real-time PCR data (2-ΔΔCT). The data are presented as average fold
change normalized to MCF7-Parental ± SEM for 4 independent experiments. RPL5 was
used as an internal control. (*) indicates a significant difference (p<0.0001) compared to
parental cells (one-way ANOVA, Tukey‘s post hoc test).
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3.3 Knockdown of CPEB2 increased breast cancer cell migration and invasion
MCF7-COX-2, MCF7-526b and MCF7-655 cells showed increased migration and
invasion compared to control MCF7 cells (Dunn et al., 2014; Majumder et al., 2015;
Majumder, Postovit, et al., 2014). Therefore, our putative target CPEB2 might also play a
role in cell migration and invasion. To assess the migratory ability of breast cancer cells
with reduced CPEB2, MCF7-CPEB2 KD cells were used in transwell migration assays.
The transwell assay is a method of measuring cell migration in a 2-D environment,
through a semi-permeable membrane. MCF7-CPEB2 KD cells had significantly
increased migratory capacity compared to MCF7-Parental or Scrambled controls (Figure
4).
Furthermore, MCF7-CPEB2 KD cells had significantly increased invasion capacity
(Figure 5) using a complementary transwell invasion method through matrigel coated
transwell inserts. Here, the ability of cells to degrade this ‗basement membrane‘ layer and
pass through the membrane was evaluated. Taking these results together, CPEB2
knockdown promotes migration and invasion in vitro.
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Figure 4. Knockdown of CPEB2 increased migration in MCF7 cells
MCF7-Parental, MCF7-Scrambled or MCF7-CPEB2 KD cells were plated in the upper
chamber of transwell inserts and incubated for 24 hours. The cells that passed through the
insert membrane were stained with Eosin and Thiasine, and counted by microscopy. A.
Images of migration transwell inserts showing number of migratory cells (scale bar: 100
µm). B. MCF7-CPEB2 KD cells had a 2-fold increase in migration compared to MCF7Parental cells. There was no difference in migration between MCF7-Parental and MCF7Scrambled cells. Data are represented as average fold change normalized to MCF7Parental ± SEM for 3 experiments. (*) indicates a significant difference (p=0.0038)
compared

to

parental

cells

(one-way

ANOVA,

Tukey‘s

post

hoc

test).
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Figure 5. Knockdown of CPEB2 increased invasion in MCF7 cells
MCF7-Parental, MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in the upper
chamber of transwell inserts coated with matrigel. After 48 hours, the cells that degraded
the layer of matrigel and passed through the insert membrane were stained with Eosin
and Thiasine, and counted. MCF7-CPEB2 KD had a 2.4-fold increase in invasion
compared to MCF7-Parental cells. There was no significant difference in invasion
between MCF7-Parental and Scrambled cells. Data are represented as average fold
change normalized to MCF7-Parental ± SEM for 3 experiments. (*) indicates a
significant difference (p=0.0127) compared to parental cells (one-way ANOVA, Tukey‘s
post hoc test).
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3.4 Knockdown of CPEB2 has no effect on breast cancer cell proliferation
To delineate the role of CPEB2 in cell proliferation, a BrdU incorporation assay was
performed. BrdU is integrated into newly synthesizing DNA during replication. The
amount of BrdU present in the cells is then used as a measure of cellular proliferation.
There was no significant difference in the amount of BrdU incorporated between Parental
and CPEB2 KD cells (Figure 6). Therefore, we concluded that CPEB2 did not play a
major role in cellular proliferation.
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Figure 6. MCF7-CPEB2 KD cells have no change in cell proliferation
MCF7-Parental, MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in 96 well
plates. BrdU incorporation was measured after 6 hours of incubation. MCF7-CPEB2 KD
cells showed no significant change (1.18 fold increase) in the average BrdU incorporated
into cells compared to MCF7-Parental cells. The data are represented as average fold
change normalized to MCF7-Parental ± SEM for 3 experiments (One-way ANOVA,
p=0.11).
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3.5 Down-regulation of CPEB2 promoted an EMT phenotype
Previous work done in this laboratory has determined that over-expressing miR-526b in
vitro decreased expression of CDH1 and up-regulated mesenchymal markers Twist1,
VIM, and Snail1 (Majumder et al., 2015). Furthermore, as shown in Figure 4, downregulating CPEB2 resulted in increased migration ability. To test whether CPEB2 KD
was associated with an EMT switch, different epithelial and mesenchymal markers were
tested (mRNA and IF). CPEB2 KD resulted in an increase in Twist1 and ZEB1, however
there was no change in Snai1 and VIM (Figure 7). Figure 8 validated that Twist1
expression increased at the protein level as well. At the same time, E-Cadherin levels
decreased with CPEB2 KD (Figure 9). Collectively, we determined that CPEB2 KD
decreases E-Cadherin protein and increases Twist1 and Zeb1 in MCF7 cells, thus has an
important role in EMT.
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Figure 7. MCF7-CPEB2 KD cells have increased expression of mesenchymal
marker Twist1
MCF7 cells transfected with human CPEB2 siRNA were compared to scrambled control
transfected cells for mesenchymal markers using relative quantification by real-time PCR
(2-ΔΔCT). MCF7-CPEB2 KD cells had a 1.6 fold increase in Twist1 expression compared
to MCF7-Scrambled cells (p=0.0104). Furthermore there was a trend towards increased
ZEB1 in CPEB2 KD cells (p=0.0556). There was no change in SNAI1 and VIM between
CPEB2 KD and control groups. The data are presented as average fold change
normalized to MCF7-Scrambled ± SEM for 3 experiments. RPL5 was used as an internal
control. (*) indicates a significant difference (unpaired t-test).
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Figure 8. MCF7-CPEB2 KD cells have increased expression of mesenchymal
marker Twist1
A. Twist1 antibody (1:250 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD cells fixed onto coverslips. Cells were imaged using Olympus FV1000.
Representative images are shown at the same magnification (scale bar: 100 µm, bottom
right panel). DAPI is shown as blue nuclei staining and Twist1 is shown as green
cytoplasmic staining, and merged shows both. B. Quantification of representative
immuno-fluorescence images was performed using ImageJ. Data are presented as the
average of raw integrated density divided by cell area. MCF7-CPEB2 KD cells had a 2.6
fold increase in Twist1 intensity compared to MCF7-Scrambled. The data are presented
as average fold change normalized to MCF7-Scrambled ± SEM. (*) indicates a
significant difference compared to Scrambled (unpaired t-test p<0.0001).
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Figure 9. MCF7-CPEB2 KD cells have decreased expression of epithelial marker ECadherin
A. E-Cadherin antibody (1:250 in 4% BSA in PBS) was added onto MCF7-Scrambled
and CPEB2 KD cells fixed onto coverslips. Cells were imaged using Olympus FV1000.
Representative images are shown at the same magnification (scale bar: 100 µm, bottom
right panel). DAPI is shown as blue nuclei staining and E-Cadherin is shown as green cell
membrane staining, and merged shows both. B. Quantification of immuno-fluorescence
pictures using ImageJ. Data are represented as the average of raw integrated density
divided by cell area. MCF7-CPEB2 KD cells had 67% reduced E-Cadherin staining
intensity compared to MCF7-Scrambled. Data are presented as average fold change
normalized to MCF7-Scrambled ± SEM. (*) indicates a significant difference (unpaired ttest p<0.0001).
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3.6 Down-regulation of CPEB2 stimulated a SLC phenotype
MCF7-COX-2 cells demonstrated higher proportion of ALDHhighCD44+ cells, increased
tumoursphere forming ability when cultured under ultra-low attachment conditions and
higher expression of miR-655 and miR-526b compared to MCF7-Mock transfected cell
(Majumder, Postovit, et al., 2014). Furthermore, MCF7-526b cells cultured in 6 well
ultra-low attachment plates demonstrated higher spheroid formation efficiency than
MCF7-Mock cells (Majumder et al., 2015). Because these results suggest increased SLC
phenotype in MCF7-COX2 and MCF7-526b cells, we next investigated the role of
CPEB2 KD on SLC phenotype.
CPEB2 siRNA transfected cells were maintained in non-adherent conditions for 8 days.
Real-time PCR demonstrated that MCF7-CPEB2 KD cells retained reduced CPEB2
expression compared to MCF7-Scrambled cells for the duration of the spheroid formation
assay (8 days, Figure 10). MCF7-CPEB2 KD cells demonstrated higher spheroid
formation efficiency compared to scrambled control cells (Figure 11). Different markers
for SLC were also tested for MCF7-CPEB2 KD and MCF7-Scrambled cells cultured in
monolayer and tumoursphere conditions. MCF7-CPEB2 KD cells showed a higher
proportion of ALDH1 positive cells in monolayers compared to scrambled controls
(Figure 12). In addition, Figure 13 demonstrates that CPEB2 KD tumourspheres also
retained higher expression of ALDH1. CPEB2 KD cells also showed higher Nanog
expression in monolayer and tumourspheres (Figure 14 and 15). Furthermore, SOX-2
expression was demonstrated to be higher in CPEB2 KD tumourspheres compared to
scrambled control tumourspheres (Figure 16). Collectively, we demonstrated that CPEB2
KD promotes a SLC phenotype, with increased spheroid formation efficiency and
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Figure 10. Eight days after siRNA transfection, MCF7-CPEB2 KD cells retained
lower expression of CPEB2
MCF7 cells were transfected with human CPEB2 siRNA (1 µM) and universal scrambled
control siRNA. Eight days after transfection, MCF7-CPEB2 KD demonstrated a 45%
reduction in CPEB2 compared to MCF7-Scrambled cells using relative quantification of
real-time PCR (2-ΔΔCT). Data are presented as average fold change normalized to MCF7Scrambled ± SEM for 3 experimental replicates. RPL5 was used as an internal control.
(*) indicates a significant difference compared to control cells (unpaired t-test,
p=0.0007).
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Figure 11. MCF7-CPEB2 KD cells demonstrated increased spheroid formation
MCF7-Scrambled and MCF7-CPEB2 KD cells were plated in 96 well ultra-low
attachment plates at a concentration of 5 cells per well. After 7 days, spheroids greater
than 60 µm were counted manually under bright-field microscopy. Spheroid formation
efficiency was calculated as the ratio of number of spheroids formed to number of cells
plated. MCF7-CPEB2 KD cells had a higher SFE (0.13) than MCF7-Scrambled cells
(0.10). (*) indicates a significant difference (unpaired t-test, p=0.0411, n=3).

55

Figure 12. MCF7-CPEB2 KD cells grown in monolayer have increased expression of
ALDH1
A. ALDH1 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD cells grown in monolayers. Cells were imaged using an Olympus FV1000
fluorescent microscope. All image panels are at the same magnification (scale bar: 100
µm, bottom right panel). DAPI is shown as blue nuclei staining and ALDH1 is shown as
green cytoplasmic staining, and merged shows both. B. Quantification of ALDH1
expression. Data are presented as ratio of positive cells to the total number of DAPI+
cells normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a
3.8 fold increase in ALDH1 positive cells compared to MCF7-Scrambled cells. (*)
indicates a significant difference (unpaired t-test, p=0.0389).
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Figure 13. MCF7-CPEB2 KD tumourspheres have increased expression of ALDH1
A. ALDH1 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom
right panel). DAPI is shown as blue nuclei staining and ALDH1 is shown as green
cytoplasmic staining, and merged shows both. B. Quantification of ALDH1 expression.
Data are presented as ratio of positive cells to the total number of DAPI+ cells
normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 2.6
fold increase in ALDH1 positive cells compared to MCF7-Scrambled. (*) indicates a
significant difference (unpaired t-test, p=0.0428).
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Figure 14. MCF7-CPEB2 KD cells grown in monolayer demonstrated increased
Nanog expression
A. Nanog antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD cells grown in monolayers. Cells were imaged using an Olympus FV1000
fluorescent microscope. All image panels are at the same magnification (scale bar: 100
µm, bottom right panel). DAPI is shown as blue nuclei staining and Nanog is shown as
green nuclear staining, and merged shows both. B. Quantification of Nanog expression.
Data are presented as ratio of positive cells to the total number of DAPI+ cells
normalized to MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated 6.5 fold
increase in Nanog positive cells compared to MCF7-Scrambled. (*) indicates a
significant difference (unpaired t-test, p=0.0064).
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Figure 15. MCF7-CPEB2 KD tumourspheres demonstrated increased Nanog
expression
A. Nanog antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom
right panel). DAPI is shown as blue nuclei staining and Nanog is shown as green nuclear
staining, and merged shows both. B. Quantification of Nanog expression. Data are
presented as ratio of positive cells to the total number of DAPI+ cells normalized to
MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 4.1 fold increase in
Nanog positive cells compared to MCF7-Scrambled. (*) indicates a significant difference
(unpaired t-test, p< 0.0001).
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Figure 16. MCF7-CPEB2 KD tumourspheres have increased SOX-2 expression
A. SOX-2 antibody (1:300 in 4% BSA in PBS) was added onto MCF7-Scrambled and
CPEB2 KD tumourspheres. Cells were imaged using an Olympus FV1000 fluorescent
microscope. All image panels are at the same magnification (scale bar: 100 µm, bottom
right panel). DAPI is shown as blue nuclei staining and SOX-2 is shown as green nuclear
staining, and merged shows both. B. Quantification of SOX-2 staining. Data are
presented as ratio of positive cells to the total number of DAPI+ cells normalized to
MCF7-Scrambled controls. MCF7-CPEB2 KD cells demonstrated a 4.4 fold increase in
Nanog positive cells compared to MCF7-Scrambled. (*) indicates a significant difference
(unpaired t-test, p=0.002).
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3.7 COX-2 and EP4 inhibition increased CPEB2 expression
We have previously shown that blocking COX-2 activity and EP4 signaling resulted in
reduced angiogenesis, lymphangiogenesis, tumour growth and metastasis to the lungs
(Xin et al., 2012). Furthermore, MCF7 cells treated with PGE2 and selective EP4 agonist
demonstrated an increase in miR-655 and miR-526b levels, while treatment with COX-2
inhibitor and EP4 antagonists resulted in decreased miRNA levels (Majumder et al.,
2015; Majumder, Postovit, et al., 2014). To examine the ability of COX-2 activity and
EP4 signaling to modulate CPEB2 expression, MCF7-COX-2 cells were treated with
selective COX-2 inhibitor (Celecoxib) and EP4 antagonist (ONO-AE3-208, ONO), while
MCF7 cells were treated with PGE2 (EP1-4 ligand) and EP4 agonist (PGE1OH). Figure
17 demonstrates that MCF7-COX-2 cells treated with Celecoxib had significantly higher
CPEB2 expressions at both 10 µM and 20 µM compared to DMSO treated cells. At the
same time, MCF7-COX2 cells treated with ONO also had significantly higher expression
of CPEB2 at 20 µM compared to DMSO treated cells (Figure 17). Surprisingly, MCF7
cells treated with PGE2 and PGE1OH demonstrated no change in CPEB2 expression
compared to EtOH treated controls (Figure 18). Therefore, we were able to demonstrate
that only blocking COX-2 activity and EP4 signaling could modulate CPEB2 expression.
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Figure 17. Cells treated with EP4 antagonist and COX-2 specific inhibitors have
increased CPEB2 expression
MCF7-COX-2 cells were treated with A. selective COX-2 inhibitor Celecoxib, or B. EP4
Antagonist ONO-AE3-208 at two different concentrations (10 µM and 20 µM), and
compared to DMSO (0.0003%) control after for 24 hours culture. MCF7-COX-2 cells
treated with Celecoxib at 10 µM and 20 µM showed a 1.6 and 3.3 fold increase in
CPEB2 expression compared to DMSO (one-way ANOVA, Tukey‘s post hoc test,
p<0.0001). MCF7-COX-2 cells treated with ONO at 20 µM showed a 1.25 fold increase
in CPEB2 expression compared to DMSO treated cells (one-way ANOVA, Tukey‘s post
hoc test, p=0.0391). The data are presented as average fold change normalized to DMSO
treated cells ± SEM for 3 experiments. (*) indicates a significant difference.

67

A.

B.

68

Figure 18. Cells treated with PGE2 and EP4 Agonist demonstrated no change in
CPEB2 expression
MCF7 cells were treated with 10 µM PGE2 (EP1-4 ligand), 10 µM PGE1OH (EP4
agonist), and compared to 0.13% EtOH control after 24 hours culture. There were no
significant changes in CPEB2 expression in either treatment. The data are presented as
average fold change normalized to EtOH treated cells ± SEM for 3 experiments (one-way
ANOVA, p=0.7065).
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4

DISCUSSION AND CONCLUSIONS

70

4.1 Summary of Findings and Conclusions
Objective 1: To investigate if there is an inverse relationship between expression levels of
a) CPEB2 and COX-2 and b) CPEB2 and miR-655 or miR-526b in human breast cancer
cell lines.
Expression of COX-2, miR-655, miR-526b and CPEB2 were tested in MCF7, SKBR3,
MDAMB231 and MCF7-COX2 cell lines. High COX-2 cell lines such as MCF7-COX-2
and MDA-MB-231 demonstrated high expression of miR-655 and miR-526b and low
expression of CPEB-2 compared to low COX-2 cell lines such as MCF7 and SKBR3.
The observed association between high COX-2, high miRNA and low CPEB2
expression, validates the inverse relationship demonstrated by the differential gene and
miRNA microarray analysis (Majumder et al., 2015).

Objective 2: To investigate the functional role of CPEB2 in human breast cancer.
CPEB2 expression was down-regulated using siRNAs in MCF7 (low COX-2/miRNAs)
cells. The resultant MCF7-CPEB2 KD cells demonstrated increased migration and
invasion in transwell assays, with no change in cellular proliferation rates. Furthermore,
CPEB2 down-regulation was also associated with an EMT phenotype where E-Cadherin
protein decreased and Twist1 mRNA and protein increased. There was also an increase in
ZEB1 mRNA. Additionally, MCF7-CPEB2 KD cells displayed increased tumoursphere
forming ability in ultra-low attachment plates. When tested for different SLC-associated
maker expression, CPEB2 KD cells had a higher frequency of ALDH1, Nanog and SOX-
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2 expressing cells. These data suggest that CPEB2 is anti-migratory and anti-invasive in
vitro, and down-regulation of CPEB2 results in a more aggressive breast cancer
phenotype. Thus, CPEB2 expression can also be implicated in the metastatic cascade
during COX-2 mediated breast cancer progression.

Objective 3: To investigate the effects of COX-2 inhibitor, and PGE2 (EP1-4 ligand), EP4
agonist and antagonist treatments on CPEB2 levels.
MCF7-COX-2 cells were first treated with Celecoxib (selective COX-2 inhibitor) and
ONO-AE3-208 (selective EP4 antagonist), and DMSO control. Both treatments resulted
in an increase in CPEB2 expression compared to DMSO treated cells, as expected. Thus
CPEB2 expression in high COX-2 cells is dependent on both COX-2 and EP4 activity.
Surprisingly, activating the EP receptors (with PGE2) and EP4 receptor (with selective
agonist PGE1OH) in low COX-2/high CPEB2 cells resulted in no significant change in
CPEB2 expression. These data suggest that down-regulation of CPEB2 in high CPEB2
expressing cells is possibly regulated by alternate signaling pathways outside of EP
activity. Therefore, it is likely that cells might have different mechanisms of upregulating and down-regulating CPEB2.
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4.2 Contribution to the Current Field of Research
The role of COX-2 in cancer progression is widely recognized. In vivo mouse studies
have shown that deletion of COX-2 results in reduced intestinal tumourigenesis (Oshima
et al., 1996). At the same time, patients who were treated with COX-2 inhibitors or lowdose aspirin demonstrated a decrease in the number of polyps formed and fatal colon
cancer (Thun et al., 1991). In breast cancer, high COX-2 has been associated with an
aggressive breast cancer phenotype, with increased invasion, and decreased disease free
survival rates (Barnes, Haywood, Flint, Knox, & Bundred, 2006; Larkins, Nowell, Singh,
& Sanford, 2006; Majumder, Postovit, et al., 2014). Additionally, COX-2 inhibitors in
breast cancer displayed chemo-preventive properties (Harris et al., 2000; Harris, 2009;
Majumder, Xin, Liu, Girish, et al., 2014; Xin et al., 2012). Unfortunately, use of COX-2
inhibitors for a prolonged period revealed serious thromboembolic side-effects in a subset
of patients (Fitzgerald, 2004; Nussmeier et al., 2005). Therefore, our lab is investigating
downstream effectors of the COX-2 pathway as potential therapeutic targets in high
COX-2 breast cancer.
Our laboratory has previously established that COX-2 exerts its effects through overproduction of PGE2 activating the prostanoid receptor EP4 (Majumder, Xin, Liu, Girish,
et al., 2014; Timoshenko et al., 2004, 2003; Xin et al., 2012). Both increased COX-2
activity and stimulation of EP4 resulted in increased expression of miR-655 and miR526b in breast cancer cells. Both miRNAs revealed similar oncogenic properties
including SLC induction in vitro (Dunn et al., 2014; Majumder et al., 2015). MiRNAs
play an important role in cancer. These small non-coding RNA molecules bind and
down-regulate the expression of certain target genes. Since we have found both miR-
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526b and miR-655 to be oncogenic in our lab, by extension we believe that their target
gene, CPEB2, should have tumour-suppressor-like functions. The underlying purpose of
this study was to identify the functional role of CPEB2 in breast cancer progression.

4.3 Role of CPEB2 in breast cancer cell migration, invasion, SLC induction and
EMT
We observed that high COX2, high miRNA breast cancer cell lines have decreased
CPEB2. Both COX-2 induced miR-655 and miR-526b have been shown to increase
cellular migration and invasion. Therefore, we predicted that the gene target CPEB2
should be anti-migratory and anti-invasive. As expected CPEB2 KD cells showed
increased migration and invasion in transwell assays, supporting our hypothesis that
CPEB2 plays an anti-oncogenic role in breast cancer. Interestingly, a recent study has
shown that miR-550a is pro-metastatic in hepatocellular carcinoma (Tian et al., 2012).
MiR-550a binds to and down-regulates CPEB4. Gain-of function studies have
demonstrated that CPEB4 is able to suppress miR-550a induced migration and invasion
(Tian et al., 2012). Additionally, miR-92 and miR-26 both bind to the 3‘UTR of CPEB2,
suggesting that CPEB2 contains functional miRNA binding sites (Morgan et al., 2010).
In a previous study, CPEB1 was shown to be SLC suppressive. Ectopic CPEB1
expression induced differentiation of glioma stem cells and reduced spheroid formation
(Yin et al., 2014). In addition, CPEB1 was shown to reduce the expression of SLC
markers SOX-2 and Nestin and increase expression of differentiation marker GFAP (Yin
et al., 2014). In the present project, we extensively explored the ability of CPEB2 KD to
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increase SLC properties of breast cancer cells in vitro. We found that CPEB2 KD cells
had increased ability to form spheroids, and displayed increased expression of SOX-2,
Nanog and ALDH1. Thus, we demonstrate for the first time that CPEB2 suppresses SLC
phenotype in human breast cancer.
EMT has also been implicated with increased invasion, metastasis and cancer progression
(Thiery, 2002), and has more recently associated with SLCs (Mani et al., 2008). Cells
transfected with Snail and Twist1 over-expressing plasmids had increased tumoursphere
forming ability and were enriched for stem cell markers indicated by a CD44high/CD24low
cells. Conversely, mammary epithelial cells sorted for CD44high/CD24low population
showed high expression levels of EMT-associated genes, for instance low levels of
CDH1 and high levels of CDH2 (Mani et al., 2008). In our studies, we found that CPEB2
KD decreased expression of E-Cadherin protein and increased expression of
mesenchymal marker Twist1. Thus, CPEB2 KD cells were enriched in both SLCs and
resembled an EMT-like phenotype. A previous study demonstrated that CPEB2 is a
negative regulator of EMT progression and Twist1 expression (Nairismägi et al., 2012).
EMT phenotype is considered to be a promoter of cell motility. Present observation of
increased migration may be a consequence of EMT in CPEB2 KD cells. Taken together,
CPEB2 stimulation might represent an important target for the prevention of cancer
progression.
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4.4 Role of COX-2 activity, EP4 Agonists and Antagonists in breast cancer
Multiple studies from other laboratories and ours have demonstrated the importance of
EP4 signaling in COX-2 mediated breast cancer progression. EP4 is a downstream target
in the COX-2 pathway that avoids the disruption of prostanoids such as PGI2 and
associated adverse cardiovascular events (Graham, 2006). As such EP4 represents a
promising therapeutic target in breast cancer. EP4 has previously been shown to regulate
proliferation, invasion and immune-suppression of natural killer cells (Ma et al., 2013;
Robertson et al., 2008). Furthermore, the EP4 receptor has been linked to angiogenesis,
lymphangiogenesis and metastasis (Timoshenko et al., 2006; Xin et al., 2012). COX-2
up-regulation of EP4 mediated signaling also increases the expression of oncogenic miR526b and miR-655 (Majumder et al., 2015; Majumder, Postovit, et al., 2014). By
extension, we expected that EP4 antagonists should increase CPEB2 levels in high COX2 cells. MCF7-COX-2 cells were treated with Celecoxib (selective COX-2 inhibitor) and
ONO-AE3-208 (EP4 antagonist). As expected, both treatments in high COX-2 cells
displayed high CPEB2 mRNA levels. Interestingly, Celecoxib induced a greater upregulation of CPEB2 than ONO-AE3-208 suggesting that CPEB2 expression might be
modulated through other EP receptors as well. Surprisingly, treatment with PGE2 and
EP4 agonist in high CPEB2 MCF7 cells could not suppress CPEB2 expression. Thus, it
is likely that EP4 signaling is just one of the players regulating CPEB2 expression in
CPEB2 high cells, suggesting that CPEB2 up-regulation and down-regulation have
different mechanisms. Since we could demonstrated an increase in CPEB2 expression
following EP4 antagonist treatment, low CPEB2 might be used as a marker for EP4
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targeted therapy used in conjunction with traditional therapy in high COX-2 breast
cancer.

4.5 Limitations of the Study
CPEB2 gene manipulations were only tested in one cell line, MCF7, which is a poorly
metastatic breast cancer cell line. Ideally inclusion of a non-tumourgenic mammary
epithelial cell line such as MCF10A would strengthen the present study. Furthermore, a
naturally occurring CPEB2 low cell line, such as MDAMB231, could also have been
manipulated to examine CPEB2 gain-of-function effects. Another limitation of the
present study is that CPEB2 levels were measured at the RNA level and not protein level.
Unfortunately, at this time there is no reliable and commercially available antibody for
CPEB2, therefore changes at the protein level could not be addressed. There are currently
six different predicted isoforms of CPEB2 (CPEB2 A-F, Table 4). Thus, deciphering the
role of each isoform will be an interesting and important part of future studies to
understand the role of CPEB2 in breast cancer.
Our proliferation assay using 6 h BrdU uptake did not reveal any change in proliferation
in CPEB2 KD cells compared to control cells. The results would have been strengthened
by an additional assay such as temporal changes in viable cell numbers for a longer
period such as 72 hours using a MTT assay.
To examine the SLC phenotype, an in vitro assay for spheroid formation efficiency was
conducted. This was supplemented with immuno-fluorescence images at both monolayer
and tumoursphere for SLC markers ALDH1, Nanog and SOX-2. This section can be
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further improved by an examination of SLC markers at the transcription level and
measurements of ALDH activity by flow cytometry.
Another aspect of the project that can be further explored is the role of the miR-655 and
miR-526b on CPEB2 gene manipulation. By looking at the different breast cancer cell
lines, we can conclude that high COX-2, high miRNA cell lines have low CPEB2
expression. However, we cannot assume that the miRNAs directly target CPEB2. A
luciferase reporter assay can properly validate that the miRNAs target and down-regulate
CPEB2 expression.
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4.6 Future Directions: Role of CPEB2 in Hypoxia
Cancer cells with a rapid proliferation rate expand into a tumour mass. Eventually the
middle of the mass experiences cell death as the rate of oxygen diffusion is not able to
keep up with the rapidly expanding mass (Brahimi-Horn, Chiche, & Pouysségur, 2007).
One mechanism through which cancer cells adapt to low oxygen levels is by the upregulation of (HIF)-1. HIF-1 is composed of two transcription factors, inducible HIF-1α
and constitutively expressed HIF-1β. These transcription factors regulate a number of
genes that promote cell-survival such as angiongenic factors like VEGF (Brahimi-Horn et
al., 2007; Jung, Isaacs, Lee, Trepel, & Neckers, 2003).
Colorectal carcinoma cell lines exposed to hypoxic condition demonstrated an expected
increase HIF-1α (Kaidi, Qualtrough, Williams, & Paraskeva, 2006). Interestingly COX-2
protein was also up-regulated in these hypoxic conditions (Kaidi et al., 2006). A
complementary study determined that COX-2 contains a functional binding site for HIF1α (Csiki et al., 2006; Kaidi et al., 2006). Furthermore, stimulation with PGE2 has been
shown to increase HIF-1α protein (Csiki et al., 2006). These results establish a link
between COX-2 and HIF-1α.
As mentioned previously, CPEB2 binds to the 3‘ UTR of HIF-1α and modulates
translation of the protein (Chen & Huang, 2012; Hägele et al., 2009). In normal
conditions, CPEB2 interacts with eEF2 and the 3‘UTR of HIF-1α, to suppress translation
of the protein (Chen & Huang, 2012). In stressed conditions, CPEB2 dissociates from
eEF2 and HIF-1α, allowing the translation of HIF-1α protein (Chen & Huang, 2012).
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Taking the results from our study into account, it is possible that COX-2 up-regulation
suppresses CPEB2, via PGE2, EP4 and oncogenic miR-526b and miR-655, and by doing
so increases HIF-1α production in breast cancer. HIF-1α has been implicated in a positive
feedback loop, where it up-regulates COX-2. This in turn can suppress CPEB2 levels and
maintain translation of HIF-1α protein. Therefore, it would be interesting to test if there is
increased COX-2, decreased CPEB2 and increased HIF-1α in a hypoxic environment.
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Figure 19. Possible mechanism of COX-2, CPEB2 and HIF-1α Pathway in Hypoxia
Up-regulation of COX-2 enzyme results in increased prostanoid production, more
specifically increased PGE2. PGE2 can bind to four EP receptors, including EP4.
Increased EP4 signaling results in the production of two oncogenic miRNAs in breast
cancer, miR-655 and miR-526b. Both oncogenic miRNAs have target sites on CPEB2. It
is predicted that increased miRNA production results in decreased CPEB2 expression.
CPEB2 is a translational repressor of HIF-1α. With reduced CPEB2 levels, repression of
HIF-1α is alleviated. HIF-1α has binding sites on COX-2, and participates in a feed
forward loop which results in increased COX-2 production (Jung et al., 2003; Kaidi et al.,
2006; Majumder et al., 2015).
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4.7 Conclusions
In this study it was observed that high COX-2 and high miRNA (miR-655 and miR-526b)
expressing breast cancer cells lines have low CPEB2 expression. As determined by in
vitro assays, CPEB2 KD cells revealed increased cellular migration and invasion, without
any effect on proliferation. For the first time, we showed that CPEB2 KD has a role in
SLC induction, indicated by increased tumoursphere formation and expression of SLC
markers ALDH1, Nanog and SOX-2. Also, CPEB2 KD cells exhibited EMT
demonstrated by reduced E-Cadherin protein levels and increased Twist1 expression. Our
results also reveal that CPEB2 expression could be reduced by blocking EP4 signaling
with antagonists. These results suggest that CPEB2 is a tumour-suppressor-like gene and
down-regulation of this gene results in an aggressive breast cancer phenotype.
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Table 1: Summary of breast cancer cell lines used in this project (ATCC, 2015;
Chavez, Garimella, & Lipkowitz, 2010; Hackett et al., 1977; Holliday & Speirs,
2011; Kao et al., 2009; Lehmann et al., 2011)

Cell Line

HS578T

MCF7

Classification

Basal B

Estrogen
receptor
(ER)

Progesterone
receptor
(PR)

HER2

—

—

—

+

+

—

Luminal A

—

epithelial

Luminal A

mammary
gland/breast

adenocarcinoma

mammary
gland,
breast; derived from
metastatic
site:
pleural effusion

adenocarcinoma

mammary
gland/breast; derived
from metastatic site:
pleural effusion

adenocarcinoma

mammary
gland/breast; derived
from metastatic site:
pleural effusion

ductal carcinoma

mammary
gland;
derived
from
metastatic
site:
pleural effusion

—
epithelial

Tissue

adenocarcinoma

+

HER2

+

Disease

—
epithelial

+
T47D

—

Basal B

—
SKBR3

epithelial

epithelial

—
MDAMB231

Cell Type
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Table 2: Probes used for real-time PCR
Probe

Company

Catalog Assay ID
Number

CPEB2 TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs01039673_m1

hsa-miR-526b TaqMan® MicroRNA Assay

Life Technologies 4427975 2382

hsa-miR-655 TaqMan® MicroRNA Assay

Life Technologies 4427975 1612

PTGS-2 (COX2) TaqMan® Gene Expression Assay Life Technologies 4427975 Hs00153133_m1
RNU44 TaqMan® Gene Expression Assay

Life Technologies 4427975 1094

RNU48 TaqMan® MicroRNA Assay

Life Technologies 4427975 1006

RPL5 TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs03044958_g1

SNAI1 TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs00195591_m1

TWIST1 TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs01675818_s1

VIM (Vimentin) TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs00185584_m1

ZEB1TaqMan® Gene Expression Assay

Life Technologies 4331182 Hs00232783_m1
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Table 3: Antibodies used for IF
Antibody

Raised in

Dilution Company
(1:x)

Catalog
Number

E-Cadherin

Rabbit

1000

Cell Signaling Technology

31955

SOX-2

Mouse

300

BD Biosciences

561593

Twist1

Rabbit

500

Santa Cruz Biotechnology

SC_15393

Vimentin

Mouse

500

EMD Millipore

MAB3400

CF488A anti-Mouse IgG
(H+L)
Goat

400

Biotium

20018-1

CF488A anti-Rabbit IgG
(H+L)
Goat

400

Biotium

20019-1
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Table 4: CPEB2 Isoforms based on BLAST and UniProt (Universal Protein
Resource) search. All isoforms are compared to CPEB2 isoform D

Nucleic

Amino

Difference from

Molecular Weight

acids

acids

isoform D

(kDa)

6878 bp

1034 aa

Isoforms

isoform D

The same

109.8 kDa

Missing sequences
isoform A

6764 bp

559 aa

61.7 kDa
1950-2034

Missing sequences
isoform B

6854 bp

589 aa

64.9 kDa
2175-2199

Missing sequences
isoform C

6797 bp

1007 aa

106.9 kDa
1950-2034

Missing sequences
isoform E

6788 bp

1007 aa

106.9 kDa
1950-2034

Missing sequences
isoform F

6773 bp

562 aa

62.1 kDa
1950-2034
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Table 5: Abstract of COX-2/EP4/Notch-Wnt Axis in Breast Cancer Cell Induction
Paper (Majumder et al. submitted Oncogene)
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